PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34523744-7	2021	Median(IQR) viral load(VL) in log copies/ml was one log lower in ezetimibe group versus non-ezetimibe group (4.1 (3.7-5.3) vs. 5.1 (4.4-5.5), p = 0.01), and highest VL was also lower in ezetimibe group (4.2 (3.7-5.4) vs. 5.4 (4.7-5.9), p = 0.006).	Ezetimibe	65-74	modulator of VRAC current 1	Homo sapiens	23-25	
34523744-7	2021	Median(IQR) viral load(VL) in log copies/ml was one log lower in ezetimibe group versus non-ezetimibe group (4.1 (3.7-5.3) vs. 5.1 (4.4-5.5), p = 0.01), and highest VL was also lower in ezetimibe group (4.2 (3.7-5.4) vs. 5.4 (4.7-5.9), p = 0.006).	Ezetimibe	186-195	modulator of VRAC current 1	Homo sapiens	23-25	
34523744-7	2021	Median(IQR) viral load(VL) in log copies/ml was one log lower in ezetimibe group versus non-ezetimibe group (4.1 (3.7-5.3) vs. 5.1 (4.4-5.5), p = 0.01), and highest VL was also lower in ezetimibe group (4.2 (3.7-5.4) vs. 5.4 (4.7-5.9), p = 0.006).	Ezetimibe	186-195	modulator of VRAC current 1	Homo sapiens	165-167	
34523744-8	2021	We concluded that ezetimibe bridge therapy might be associated with reduction in HCV VL while waiting for DAA initiation in HCV+ to HCV negative KT recipients.	Ezetimibe	18-27	modulator of VRAC current 1	Homo sapiens	85-87